Endogenex

Endogenex is a medical technology company focused on developing new treatment options for people living with type 2 diabetes. Founded in partnership with Mayo Clinic, the company is working to address the condition by targeting metabolic signaling in the small intestine, rather than focusing only on its downstream effects. Its Endogenex system uses a novel endoscopic approach to deliver precise, controlled, non-thermal pulsed electric fields to the duodenum. The approach is designed to affect poorly functioning signaling cells and help restore the intestine’s natural signaling process, with the goal of improving the body’s ability to control blood glucose and potentially slowing disease progression.

The system is investigational and is being evaluated in clinical studies; it is not for sale in any geography. The pivotal ReCET Study evaluated its use in people with type 2 diabetes, enrolled participants at sites in the United States and Australia, and is now closed to enrollment. Endogenex provides information for patients, clinicians, providers, and study teams, including resources about the technology and clinical research.